University of Cambridge-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2024

  1. Addressing Ancestry and Sex Bias in Pharmacogenomics

    Annual review of pharmacology and toxicology, Vol. 64, pp. 53-64

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. Generalisation of genomic findings and applications of polygenic risk scores

    BMC Medical Genomics

  3. Genetic signature detected in T cell receptors from patients with severe COVID-19

    iScience, Vol. 26, Núm. 10

  4. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. Implementation of individualised polygenic risk score analysis: a test case of a family of four

    BMC Medical Genomics, Vol. 15

  2. Transferability of genetic risk scores in African populations

    Nature Medicine, Vol. 28, Núm. 6, pp. 1163-1166

2021

  1. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  2. Editorial: Personal Genomes: Accessing, Sharing, and Interpretation

    Frontiers in Genetics

  3. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

  4. The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study

    Schizophrenia Research, Vol. 236, pp. 69-79

  5. Whole Genome Interpretation for a Family of Five

    Frontiers in Genetics, Vol. 12

2020

  1. Assessing irritability in patients with stroke: psychometric properties of the Irritability Questionnaire

    Brain Injury, Vol. 34, Núm. 1, pp. 115-121

  2. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  3. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

    Journal of Hepatology, Vol. 71, Núm. 2, pp. 397-408

2018

  1. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2016

  1. Athlome project consortium: A concerted effort to discover genomic and other "omic" markers of athletic performance

    Physiological Genomics, Vol. 48, Núm. 3, pp. 183-190

2014

  1. Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations

    Schizophrenia Bulletin, Vol. 40, Núm. 4, pp. 729-736